Nail and scalp changes reported more often among GLP-1 users
People taking GLP-1 receptor agonists reported nail detachment more than four times as often as nonusers with obesity or type 2 diabetes, according to the first controlled study to examine the medications' potential effects on nail health. The findings were presented Oct. 1 at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna.
The study compared 575 GLP-1 receptor agonist users with 1,329 controls with type 2 diabetes and/or obesity recruited in France, the U.S., Brazil, and Mexico. Thirty-nine per cent of users reported nail detachment versus 9% of controls; nail discolouration affected 46% versus 17%. Two-thirds of users reported at least one nail disorder, versus 53% of controls, and differences remained significant among participants who had lost weight.
A companion study of the same participants found unusual hair loss in 50% of users versus 34% of controls, and loss of hair volume or density in 42% versus 19%. Hair loss beginning after treatment initiation was more than twice as common among users, and scalp redness roughly three times as frequent. Most hair-loss cases among users were accompanied by scalp symptoms, a pattern the investigators said suggests a possible inflammatory component beyond classical weight-loss-related shedding.
Both studies were cross-sectional and relied on patient-reported symptoms, and so can identify associations but cannot establish causation. About half of users reported nail problems before starting treatment, and adjusting for dermatologic conditions and nutritional deficiencies reduced the strength of some associations; detachment and discolouration nonetheless remained roughly two to three times more frequent among users.
"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," said study author Charles Taïeb, MD, PhD in a press release. "Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself." He is Managing Director at European Market Maintenance Assessment (EMMA).
Dr. Bruno Halioua, a dermatologist based in Paris and a study author, stressed patient awareness rather than alarm. "These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one's own initiative," he said. "Anyone who notices hair shedding, an itchy or red scalp, or nail changes should mention it to their doctor rather than discontinue therapy."
The researchers plan prospective studies with standardised dermatologic examinations and biological monitoring. The studies received institutional support from DUCRAY Laboratories (Pierre Fabre Group).
Comments